Case Study: Guiding Patient Selection for Clinical Development

Learn how a BTH identified two specifically-defined NSCLC patient populations where our client had the best chance of addressing unmet need and gaining market adoption.

Situation: A client developing a new therapy sought to prioritize the indication for clinical development that has the highest likelihood of technical and commercial success

Task: Develop a concise ranking methodology for indication options based on the client’s technology and scientific rationale, competitive density and market evolution and addressable patient populations

Actions:

• Leveraged our scientific expertise to contextualize lessons learned from technically-analogous approaches, highlighting challenges, inflection points in the field and data gaps

• Curated historical proof-of-concept data

• Utilized our expertise in oncology landscapes to concisely convey competitive density and frontrunners in each indication of interest, along with the most likely market evolution

• Tapped into our primary intel network of treating oncologists to pinpoint key areas of unmet need, and addressable patient populations

• Defined entry opportunities and challenges for top indications and framed these in terms of the client’s’ in-house assets and capabilities 

Result: Based on this comprehensive analysis, the client was able to prioritize two specifically-defined NSCLC patient populations where they have the best chance of addressing unmet need and gaining market adoption with their technology. The client used our insights to communicate a defensible rationale and continuously win confidence with investors and shareholders.

Next, BTH developed a comprehensive plan for continuous CI monitoring, including fast-turnaround email alerts that frame new developments in the context of our current narrative and shared assumptions, to keep our rationale up-to-date in line with emerging trends and transformational catalysts.